fda glp-1 compounding enforcement october 2025 semaglutide Diabetes advocacy group discourages use of compounded drugs February 17, 2026: Pennsylvania compounding – FDA Update: Current Guidelines for

Lower reliance on other medications

Ipamorelin has a smaller but growing evidence base

Un horizonte en construccin Los resultados actuales no implican que los medicamentos GLP-1 deban reemplazar las terapias conductuales ni los enfoques psicosociales

Stop using Wegovy and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat

Add a bottle to your order for just $19.99

Raise Your Brand Awareness Position your organization as a pioneer in next-generation GLP-1 therapeutics by ensuring your brand is visible to c-level executives, senior scientists, and strategic decision-makers dedicated to accelerating metabolic and neurodegenerative drug development Distinguish Yourself from the Crowd Differentiate your solutions and services in a fiercely competitive market by showcasing your breakthroughs to a focused audience actively seeking new technologies to gain a competitive edge beyond monotherapy Generate Commercial Opportunities Accelerate your business development objectives by directly engaging with decision-makers at major pharma and biotech companies by forging the crucial collaborations needed to secure your market position in the 2026 GLP-1 market Uncover the Next Market Trend Gain exclusive, front-line intelligence on the GLP-1 field, discovering emerging clinical and commercial data and strategies for high-value indication expansion into neurological disorders, cardiorenal protection and women's health Brush Shoulders with Industry Experts Directly network with key opinion leaders, speakers, and leading innovators, including representatives from major pharma, innovative biotechs ensuring you are part of the conversation defining the future of GLP-1 drug development Key Services & Solutions Our attendees from GLP-1 biopharma are looking for service and solution providers with capabilities in the below areas but not limited to: Preclinical CROs With particular interest in models of obesity including, muscle models, to validate trial findings in preclinical models Clinical CROs Contract research organisations to assist with the planning and coordinating sites for clinical trials Diagnostics & Imaging Imaging (MRIs etc) for obesity, cardiovascular, renal, metabolic as a biomarker and endpoint RWE & HEOR Real world evidence, health economics outcomes research data companies to collect and analyse the real-world data for trials Hear What Our Past Sponsors Have to Say The sessions were amazing and there was a very good opportunity to discuss and meet with all of the meeting participants Senior Director, Antaros Medical AB The quality of the program and participants, not to mention the number of opportunities to connect Director, Scientific & Business Development, Cardiomedex Audience Composition 2026 Attending Companies Included Get in Touch Take advantage of our bespoke sponsorship opportunities to achieve your commercial goals